285 related articles for article (PubMed ID: 26744740)
1. Safinamide for symptoms of Parkinson's disease.
Müller T
Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
Müller T; Foley P
Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574
[TBL] [Abstract][Full Text] [Related]
4. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Müller T
Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Abreu D; Ferreira JJ
Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Stocchi F; Torti M
Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
[TBL] [Abstract][Full Text] [Related]
7. Safinamide in the treatment of Parkinson's disease.
Müller T
Neurodegener Dis Manag; 2020 Aug; 10(4):195-204. PubMed ID: 32648512
[TBL] [Abstract][Full Text] [Related]
8. Safinamide: a new hope for Parkinson's disease?
Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
[TBL] [Abstract][Full Text] [Related]
9. Safinamide for the treatment of Parkinson's disease.
Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
[TBL] [Abstract][Full Text] [Related]
11. An expert opinion on safinamide in Parkinson's disease.
Onofrj M; Bonanni L; Thomas A
Expert Opin Investig Drugs; 2008 Jul; 17(7):1115-25. PubMed ID: 18549347
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
Perez-Lloret S; Rascol O
Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
[TBL] [Abstract][Full Text] [Related]
13. ▼ Safinamide for Parkinson's disease.
Drug Ther Bull; 2018 May; 56(5):54-57. PubMed ID: 29760163
[TBL] [Abstract][Full Text] [Related]
14. Safinamide for the treatment of Parkinson's disease.
Dézsi L; Vécsei L
Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
[TBL] [Abstract][Full Text] [Related]
15. Safinamide (Xadago) for Parkinson's disease.
Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
[No Abstract] [Full Text] [Related]
16. Safinamide in the treatment of Parkinson's disease.
Schapira AH
Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
[TBL] [Abstract][Full Text] [Related]
17. Real life evaluation of safinamide effectiveness in Parkinson's disease.
Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
[TBL] [Abstract][Full Text] [Related]
18. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Alborghetti M; Nicoletti F
Curr Neuropharmacol; 2019; 17(9):861-873. PubMed ID: 30160213
[TBL] [Abstract][Full Text] [Related]
19. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Cattaneo C; Sardina M; Bonizzoni E
J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
